Inactive Instrument

Press Releases PledPharma AB (publ) Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

Feb. 22	Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 22	Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	Apr. 24	AQ
Egetis Therapeutics' : 2023 Annual Report published	Apr. 15	PU
Egetis Therapeutics’ 2023 Annual Report published	Apr. 15	AQ
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	Mar. 29	PU
Egetis Therapeutics - Continued progress in Q4	Feb. 23	AQ
Egetis Therapeutics : – Corporate Presentation December 2023	Dec. 27	PU
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	Dec. 22	AQ
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	Dec. 19	AQ
Egetis’ Investor Day on December 19: Agenda and Registration Details	Dec. 14	AQ
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	Dec. 13	AQ
Save the Date: Egetis to host Investor Day on December 19, 2023	Dec. 01	AQ
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	Nov. 10	AQ
Egetis Therapeutics - All eyes on eventful 2024	Nov. 09	AQ
Egetis Therapeutics has resolved on directed issues of warrants and a convertible bond within the framework of the drawdown of Tranche A of the previously communicated debt financing	Nov. 07	AQ
Egetis recruits Desiree Luthman as Vice President Global Regulatory Affairs	Nov. 07	AQ
Egetis’ Nomination Committee for the 2024 Annual General Meeting	Nov. 01	AQ
Change in the number of shares and votes in Egetis Therapeutics	23-10-31	AQ
Egetis announces EMA validation of Marketing Authorisation Application for Emcitate for the treatment of MCT8 deficiency	23-10-27	AQ
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm	23-10-11	AQ
Egetis Therapeutics has secured approximately SEK 462 million in a combined financing comprising a SEK 172 million equity private placement and SEK 290 million debt financing	23-10-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PledPharma AB (publ) Nasdaq Stockholm

Equities

Press Releases

Filters